Why the study?
Post-thrombotic syndrome affects up to 50% of DVT patients with few proven treatment options once established, leaving many unanswered questions regarding optimal prevention and high-risk patient identification.
What are the current evidence-based strategies for the prevention and management of post-thrombotic syndrome in patients with deep vein thrombosis?
What are the current evidence-based strategies for the prevention and management of post-thrombotic syndrome in patients with deep vein thrombosis?
This review highlights that DOACs may be superior to VKAs for preventing post-thrombotic syndrome after DVT, while evidence for other interventions like compression stockings remains unclear.
Answers are grounded in this paper and cite their sources.
PTS burden projected to rise with aging population; leaves open optimal prevention strategies in DVT.
Post-thrombotic syndrome (PTS) is a common and potentially debilitating complication of deep vein thrombosis (DVT), affecting up to 50% of DVT patients. The consequence of this chronic condition includes reduced quality of life, increased use of the healthcare system and decreased productivity. The societal impact of this condition is projected to increase, given our ageing population and increased burden of thrombotic diseases. Despite significant recent advances in our understanding of PTS, many unanswered questions remain. Currently, there are few effective and proven options for established PTS; hence, the emphasis should be on instituting effective prevention to reduce the progression to PTS. Effective anticoagulation lowers the risk of PTS, with direct oral anticoagulants appearing to outperform vitamin-K antagonists. However, the evidence for elastic compression stockings and endovascular thrombolysis or thrombectomy techniques remains unclear. Accurate identification of individuals at high risk of developing PTS may also improve the targeting of preventative interventions. This review will examine the current body of evidence regarding PTS, with a focus on preventative strategies as well as novel biomarkers.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: